|
1
|
Hirota S, Isozaki K, Moriyama Y, Hashimoto
K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M,
et al: Gain-of-function mutations of c-kit in human
gastrointestinal stromal tumors. Science. 279:577–580. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nishida T and Hirota S: Biological and
clinical review of stromal tumors in the gastrointestinal tract.
Histol Histopathol. 15:1293–1301. 2000.PubMed/NCBI
|
|
3
|
Verweij J, Casali PG, Zalcberg J, LeCesne
A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PC,
Van Glabbeke M, et al: Progression-free survival in
gastrointestinal stromal tumours with high-dose imatinib:
Randomised trial. Lancet. 364:1127–1134. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Heinrich MC, Corless CL, Demetri GD,
Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den
Abbeele AD, Druker BJ, et al: Kinase mutations and imatinib
response in patients with metastatic gastrointestinal stromal
tumor. J Clin Oncol. 21:4342–4349. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kretz M, Siprashvili Z, Chu C, Webster DE,
Zehnder A, Qu K, Lee CS, Flockhart RJ, Groff AF, Chow J, et al:
Control of somatic tissue differentiation by the long non-coding
RNA TINCR. Nature. 493:231–235. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Klattenhoff CA, Scheuermann JC, Surface
LE, Bradley RK, Fields PA, Steinhauser ML, Ding H, Butty VL, Torrey
L, Haas S, et al: Braveheart, a long noncoding RNA required for
cardiovascular lineage commitment. Cell. 152:570–583. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee NK, Lee JH, Kim WK, Yun S, Youn YH,
Park CH, Choi YY, Kim H and Lee SK: Promoter methylation of PCDH10
by HOTAIR regulates the progression of gastrointestinal stromal
tumors. Oncotarget. 7:75307–75318. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mohammad F, Mondal T, Guseva N, Pandey GK
and Kanduri C: Kcnq1ot1 noncoding RNA mediates transcriptional gene
silencing by interacting with Dnmt1. Development. 137:2493–2499.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sun L, Goff LA, Trapnell C, Alexander R,
Lo KA, Hacisuleyman E, Sauvageau M, Tazon-Vega B, Kelley DR,
Hendrickson DG, et al: Long noncoding RNAs regulate adipogenesis.
Proc Natl Acad Sci USA. 110:3387–3392. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pandey GK, Mitra S, Subhash S, Hertwig F,
Kanduri M, Mishra K, Fransson S, Ganeshram A, Mondal T, Bandaru S,
et al: The risk-associated long noncoding RNA NBAT-1 controls
neuroblastoma progression by regulating cell proliferation and
neuronal differentiation. Cancer Cell. 26:722–737. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gupta RA, Shah N, Wang KC, Kim J, Horlings
HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, et al: Long
non-coding RNA HOTAIR reprograms chromatin state to promote cancer
metastasis. Nature. 464:1071–1076. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Niinuma T, Suzuki H, Nojima M, Nosho K,
Yamamoto H, Takamaru H, Yamamoto E, Maruyama R, Nobuoka T, Miyazaki
Y, et al: Upregulation of miR-196a and HOTAIR drive malignant
character in gastrointestinal stromal tumors. Cancer Res.
72:1126–1136. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee NK, Lee JH, Kim WK, Yun S, Youn YH,
Park CH, Choi YY, Kim H and Lee SK: Promoter methylation of PCDH10
by HOTAIR regulates the progression of gastrointestinal stromal
tumors. Oncotarget. 7:75307–75318. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lai S, Wang G, Cao X, Luo X, Wang G, Xia
X, Hu J and Wang J: KIT over-expression by p55PIK-PI3K leads to
imatinib-resistance in patients with gastrointestinal stromal
tumors. Oncotarget. 7:1367–1379. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li J, Dang Y, Gao J, Li Y, Zou J and Shen
L: PI3K/AKT/mTOR pathway is activated after imatinib secondary
resistance in gastrointestinal stromal tumors (GISTs). Med Oncol.
32:1112015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xiao Y, Jiao C, Lin Y, Chen M, Zhang J,
Wang J and Zhang Z: lncRNA UCA1 contributes to imatinib resistance
by acting as a ceRNA against miR-16 in chronic myeloid leukemia
cells. DNA Cell Biol. 36:18–25. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang H, Li Q, Tang S, Li M, Feng A, Qin L,
Liu Z and Wang X: The role of long noncoding RNA HOTAIR in the
acquired multidrug resistance to imatinib in chronic myeloid
leukemia cells. Hematology. 22:208–216. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cao K, Li M, Miao J, Lu X, Kang X, Zhu H,
Du S, Li X, Zhang Q, Guan W, et al: CCDC26 knockdown enhances
resistance of gastrointestinal stromal tumor cells to imatinib by
interacting with c-KIT. Am J Transl Res. 10:274–282.
2018.PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lin SC, Liao WL, Lee JC and Tsai SJ:
Hypoxia-regulated gene network in drug resistance and cancer
progression. Exp Biol Med (Maywood). 239:779–792. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Keith B, Johnson RS and Simon MC: HIF1α
and HIF2α: Sibling rivalry in hypoxic tumour growth and
progression. Nat Rev Cancer. 12:9–22. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rohwer N and Cramer T: Hypoxia-mediated
drug resistance: Novel insights on the functional interaction of
HIFs and cell death pathways. Drug Resist Updat. 14:191–201. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Harris AL: Hypoxia-a key regulatory factor
in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nurwidya F, Takahashi F, Minakata K,
Murakami A and Takahashi K: From tumor hypoxia to cancer
progression: The implications of hypoxia-inducible factor-1
expression in cancers. Anat Cell Biol. 45:73–78. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Semenza GL: Defining the role of
hypoxia-inducible factor 1 in cancer biology and therapeutics.
Oncogene. 29:625–634. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bristow RG and Hill RP: Hypoxia and
metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev
Cancer. 8:180–192. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nurwidya F, Takahashi F, Minakata K,
Murakami A and Takahashi K: From tumor hypoxia to cancer
progression: The implications of hypoxia-inducible factor-1
expression in cancers. Anat Cell Biol. 45:732012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Holmquist-Mengelbier L, Fredlund E,
Löfstedt T, Noguera R, Navarro S, Nilsson H, Pietras A,
Vallon-Christersson J, Borg A, Gradin K, et al: Recruitment of
HIF-1alpha and HIF-2alpha to common target genes is differentially
regulated in neuroblastoma: HIF-2alpha promotes an aggressive
phenotype. Cancer Cell. 10:413–423. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kaelin WG Jr: The von Hippel-Lindau tumour
suppressor protein: O2 sensing and cancer. Nat Rev Cancer.
8:865–873. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bertout JA, Majmundar AJ, Gordan JD, Lam
JC, Ditsworth D, Keith B, Brown EJ, Nathanson KL and Simon MC:
HIF2alpha inhibition promotes p53 pathway activity, tumor cell
death, and radiation responses. Proc Natl Acad Sci USA.
106:14391–14396. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shih JW and Kung HJ: Long non-coding RNA
and tumor hypoxia: New players ushered toward an old arena. J
Biomed Sci. 24:532017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang T, Li XN, Li XG, Li M and Gao PZ:
DNAJC6 promotes hepatocellular carcinoma progression through
induction of epithelial-mesenchymal transition. Biochem Biophys Res
Commun. 455:298–304. 2014. View Article : Google Scholar : PubMed/NCBI
|
